| Target Price | HK$24.79 |
| Price | HK$14.73 |
| Potential |
68.27%
register free of charge
|
| Number of Estimates | 4 |
|
4 Analysts have issued a price target Consun Pharmaceutical Group 2027 .
The average Consun Pharmaceutical Group target price is HK$24.79.
This is
68.27%
register free of charge
HK$27.30
85.34%
register free of charge
HK$22.83
54.96%
register free of charge
|
|
| A rating was issued by 8 analysts: 7 Analysts recommend Consun Pharmaceutical Group to buy, 1 to hold and 0 to sell. | |
| Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
|
Analyst Estimates: Analysts believe that the Consun Pharmaceutical Group stock has an average upside potential 2027 of
68.27%
register free of charge
|
| Dec '25 |
2026 Estimates |
|
|---|---|---|
| Revenue Billion HK$ | 4.00 | 4.64 |
| 15.17% | 15.88% | |
| EBITDA Margin | 35.54% | 37.35% |
| 1.56% | 5.08% | |
| Net Margin | 31.55% | 33.93% |
| 2.81% | 7.55% |
4 Analysts have issued a sales forecast Consun Pharmaceutical Group 2026 . The average Consun Pharmaceutical Group sales estimate is
This results in the following potential growth metrics:
4 Consun Pharmaceutical Group Analysts have issued a net profit forecast 2026. The average Consun Pharmaceutical Group net profit estimate is
This results in the following potential growth metrics and future Net Margins:
| Dec '25 |
2026 Estimates |
|
|---|---|---|
| Earnings Per Share HK$ | 1.48 | 1.87 |
| 15.63% | 26.35% | |
| P/E | 7.92 | |
| EV/Sales | 1.69 |
4 Analysts have issued a Consun Pharmaceutical Group forecast for earnings per share. The average Consun Pharmaceutical Group EPS is
This results in the following potential growth metrics and future valuations:
Consun Pharmaceutical Group...
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.


